Trial and error: Cross-trial comparisons of antiretroviral regimens

AIDS

Volumn 17, Issue 4, 2003, Pages 619-623

  Phillips, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antiretroviral regimens; Trials

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANALYTIC METHOD; ANTIMICROBIAL THERAPY; ANTIRETROVIRAL TREATMENT; CLINICAL TRIAL; COMPARATIVE STUDY; ERROR; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MEDICAL RESEARCH; MONITORING; PRIORITY JOURNAL; SAMPLING; SHORT SURVEY; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATA INTERPRETATION, STATISTICAL; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0037423814     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303070-00018     Document Type: Short Survey

References (37)

1. Gartland M, on behalf of the Avanti Study Group. Avanti 3: a randomized, double blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1 infected antiretriviral-naive patients. Antiviral Ther 2001 6:127-134.
2. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001, 285:1155-1163.
3. Montaner JSG, Hogg R, Raboud J, Harrigan R, O'Shaughnessy M. Antiretroviral treatment in 1998. Lancet 1998, 352:1919-1922.
4. Hammer SM, Vaida F, Bennet KK, Holohan MK, Sheiner L, Eron JJ, et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure. JAMA 2002, 288:169-180.
5. Youle MS, Tyrer M, Fisher M, Lampe F, Wilson D, Ransom D, et al. Two year outcome of a multi-drug regimen in patients who did not respond to a protease inhibitor regimen. J AIDS 2002, 29:58-61.
6. Hill AB. Observation and experiment. N Engl J Med 1953, 248:995-1001.
7. Pocock SJ. Clinical Trials: A Practical Approach. Chichester, UK: Wiley; 1983.
8. Podzamczer D, Ferret E, Consiglio E, Gatell J, Perez P, Perez J, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Ther 2002, 7:81-90.
9. van Leeuwen R. The Atlantic Study: a randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 2 year follow-up data. XIVth International Conference on AIDS. Barcelona, July 2002 [abstract MoPeB3089].
10. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873.
11. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001, 286:2560-2567.
12. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36.
13. Mallal S, Nolan D, Witt C, Masel G, Martin A, Moore C, et al. The presence of HLA-B*4701, -DRB1*0701 and -DQ3 is highly predictive of hypersensitivity to the HIV reverse transcriptase inhibitor abacavir. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 91].
14. Gervaix A, Nicolas J, Portales P, Posfay-Barbe K, Wyler CA, Segondy M, et al. Response to treatment and disease progression linked to CD4(+) T cell surface CC chemokine receptor 5 density in human immunodeficiency virus type 1 vertical infection. J Infect Dis 2002, 185:1055-1061.
15. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Socio-demographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13:1763-1769
16. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J AIDS 2000, 23:386-395.
17. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J AIDS 2001, 28:445-449.
18. Mocroft A, Miller V, Chiesi A, Blaxhult A, Katlama C, Clotet B, et al. Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antiviral Ther 2000, 5:107-112.
19. Staszewski S, Miller V, Sabin CA, Carlebach A, Berger AM, Weidmann E, et al. Virologic response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999, 13:367-373.
20. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
21. Sucupira MCA, Souza IE, Costa LJ, Scheinberg MA, Diaz RS. Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo, Brazil. Antiviral Ther 2001, 6:263-264.
22. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-86.
23. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
24. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J AIDS 2001, 28:232-239.
25. Raboud JM, Harris M, Rae S, Montaner JSG. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002, 3:118-124.
26. Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, et al. Viral rebound after suppression < 400 copies/ml on initial HAART regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2003, (in press).
27. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753-1761.
28. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
29. Porter K, Pillay D, Cane P, Dean G, Churchill D, Baily G, Drake S, et al. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J 2001, 322:1087-1088.
30. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients. The INCAS trial. JAMA 1998, 279:930-937.
31. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039-2046.
32. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001, 358:1322-1327.
33. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med, 1997, 126:946-954.
34. Lyamuya E, Olausson-Hansson E, Albert J, Mhalu F, Biberfeld G. Evaluation of a prototype Amplicor PCR assay for detection of human immunodeficiency virus type 1 DNA in blood samples from Tanzanian adults infected with HIV-1 subtypes A, C and D. J Clin Virol 2000, 17:57-63.
35. Sabin CA, Cozzi Lepri A, Phillips AN. A practical guide to applying the intention-to-treat principle to clinical trials in HIV infection. HIV Clin Trials 2000 1:31-38.
36. Sabin CA, Phillips AN. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. J Antimicrob Chemoth 2001, 47:371-375.
37. Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999, 13:2075-2082.